Molecule to Market: Inside the outsourcing space

• How to plan for life sciences events in 2025

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Luke Bilton, Co-Founder at Life Science Networks, PharmaSource and CDMO Live. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Luke, covering: How Covid exposed the complacency of event organizers in pharma services Behind the scenes of organizing CPHI Worldwide - what's it really like - chaos or calm? How companies should be thinking about event budgeting, planning and ROI in 2025 Beware 'the HIPPO' when planning which events to attend Luke Bilton is Co-Founder of Life Science Networks, a next-generation community and events organization specializing in biopharma manufacturing. The company's growing portfolio includes the PharmaSource outsourcing podcast and online community, alongside its flagship event, CDMO Live. With over 20 years experience launching and growing digital media and events businesses at companies including Informa, Future and Innovation Enterprise, Luke partnered with Chris Kilbee, former head of CPHI global events, to establish Life Science Networks. CDMO Live (World Trade Center, Rotterdam, 7-8 May 2025) brings together biopharma's manufacturing leaders to optimize their outsourcing strategy. The event's unique PartnerMatch program facilitates curated one-to-one meetings between sponsors and over 50 leading CDMOs. To find out more, visit CDMO Live Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  41:34
• Biopharma Global Supply veteran

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering: Stretching yourself by tapping into the collective wisdom of others The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin). He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  55:43
• Meet the healthcare futurist

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering: His unusual blend of experience led to a road into big pharma... Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies His views on the thorny issue of CGT products' price (and value) Opting to start his own business aimed at supporting the future of healthcare Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry. As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  52:48
• The dynamic duo driving global growth

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with James Lovett, CEO and Mike Cohen, Executive Chairman at Myonex. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering: How a family-owned pharmacy became a major global clinical trial supplies business... two generations later Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success James' decision to take on the baton and fuel organic and inorganic growth through client-centricity The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook Why this industry will always grow due to unmet medical needs and breakthroughs in science Michael’s passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university’s Katz Graduate School of Business. James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  54:00
• Biopharma Insights: Live from J.P. Morgan

  In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering: The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  --------  

  39:44

More Science podcasts

Trending Science podcasts

About Molecule to Market: Inside the outsourcing space